NovaBridge Biosciences Additional Paid in Capital, Common Stock
NovaBridge Biosciences (NBP) had Additional Paid in Capital, Common Stock of $1.53 billion as of 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-04-07
- 2023-12-31: Additional Paid in Capital, Common Stock 9.80B CNY.
- 2022-12-31: Additional Paid in Capital, Common Stock 9.58B CNY.
- 2022-06-30: Additional Paid in Capital, Common Stock 9.37B CNY.
- 2021-12-31: Additional Paid in Capital, Common Stock 9.10B CNY.
CNY
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2023-12-31 | 9.80B CNY 20-F · filed 2024-04-30 |
| 2022-12-31 | 9.58B CNY 20-F · filed 2024-04-30 |
| 2022-06-30 | 9.37B CNY 6-K · filed 2022-11-10 |
| 2021-12-31 | 9.10B CNY 20-F · filed 2023-05-01 |
| 2020-12-31 | 7.70B CNY 20-F · filed 2022-04-29 |
| 2020-09-30 | 6.72B CNY 6-K · filed 2021-02-05 |
| 2019-12-31 | 389.38M CNY 20-F · filed 2021-04-28 |
USD
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2025-12-31 | $1.53B 20-F · filed 2026-04-07 | |
| 2025-09-30 | $1.52B 6-K · filed 2025-12-18 | |
| 2025-06-30 | $1.46B 6-K · filed 2025-10-06 | |
| 2024-12-31 | $1.46B 20-F · filed 2026-04-07 | |
| 2023-12-31 | $1.47B 20-F · filed 2025-04-03 | $1.38B 20-F · filed 2024-04-30 |
| 2022-12-31 | $1.39B 20-F · filed 2023-05-01 | |
| 2022-06-30 | $1.40B 6-K · filed 2022-11-10 | |
| 2021-12-31 | $1.43B 20-F · filed 2022-04-29 | |
| 2020-12-31 | $1.18B 20-F · filed 2021-04-28 | |
| 2020-09-30 | $989.85M 6-K · filed 2021-02-05 | |
| 2019-12-31 | $55.93M 20-F · filed 2020-04-29 |